Mitomycin C inhibits recurrent Avellino dystrophy after phototherapeutic keratectomy.
OBJECTIVE
To report 4 patients with Avellino corneal dystrophy (ACD) who were treated with 0.02% mitomycin C (MMC) during phototherapeutic keratectomy (PTK).


METHODS
ACD was confirmed by polymorphism of the exon region in the BIGH3 gene using polymerase chain reaction followed by DNA sequencing analysis. Three patients with recurrent ACD and 1 patient with primary ACD underwent PTK. Intraoperative 0.02% MMC was applied topically with a soaked microsponge.


RESULTS
There was no recurrence of ACD in the heterozygotes, but there were recurrences with best-corrected visual acuity of 20/30 in the 2 homozygotes.


CONCLUSIONS
Intraoperative use of topical 0.02% MMC in conjunction with PTK may prevent or delay the recurrence of ACD for at least for 1 year.
Kim
Tae-im
TI
Department of Ophthalmology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
Pak
Jhang Ho
JH
Chae
Ju-byung
JB
Kim
Eung Kweon
EK
Tchah
Hungwon
H
D000328:Adult; D003317:Corneal Dystrophies, Hereditary / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007432:Intraoperative Period; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy; D055502:Secondary Prevention; D014792:Visual Acuity
D019384:Nucleic Acid Synthesis Inhibitors; D009883:Ophthalmic Solutions; D016685:Mitomycin